Catalog No.
DHG52008
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fab Fused with a fragment of Pseudomonas exotoxin A.
Clonality
Monoclonal
Target
LMB-100
Concentration
0.4 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13421
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LMB-100, LMB 100, LMB100
Clone ID
LMB-100
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers., PMID:38706610
Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures., PMID:36409889
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel., PMID:36208017
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin., PMID:32870522
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation., PMID:32695104
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models., PMID:32611684
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors., PMID:32605175
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma., PMID:31792036
Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy., PMID:30933045
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors., PMID:30384408
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1., PMID:30213644
Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity., PMID:29581296
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin., PMID:29431691
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer., PMID:29273809
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway., PMID:29152082
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity., PMID:28674083
Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes., PMID:27999204
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, PMID:27863199
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response., PMID:27635089
Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis., PMID:27601652
Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1., PMID:26719540
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results., PMID:26111884
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers., PMID:25239937
In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer., PMID:24928849
For research use only. Not for human or drug use.
